Positive Halneuron® Phase 2b Interim Data Boosts Dogwood Therapeutics, Cash Runway Extended
DWTX sits 20% above its 52-week low of $2.6.
Summary
Dogwood Therapeutics reported its fourth quarter and full year 2025 financial results, alongside significant operational updates. The company announced positive interim data from its Halneuron® Phase 2b trial, indicating the drug is separating from placebo, with top-line results anticipated in Q3 2026. This clinical progress is a crucial de-risking event for their lead product candidate. Additionally, Dogwood completed a financing of up to $26.9 million in January 2026, with $12.5 million already received, which is expected to fund operations through the Phase 2b data readout and into the fourth quarter of 2026. While the full-year net loss widened to $35.5 million, the market is likely to prioritize the positive clinical development and the secured cash runway for this development-stage biotech. Investors will now focus on the full Phase 2b results and further financing updates.
At the time of this announcement, DWTX was trading at $3.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107.2M. The 52-week trading range was $2.60 to $9.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.